Georges Gemayel Appointed Non-Executive Chairman Of Enterome

ENTEROME Bioscience SA, a pioneer in the development of therapeutic solutions (drugs and diagnostics) based on a deep understanding of the gut microbiome, is pleased to announce that Georges Gemayel PhD has joined the Enterome board as a Non-executive Chairman. He replaces Bernard Gilly, who becomes a Non-executive Director.

Dr Gemayel has over 25 years of experience in the pharmaceutical industry, including management and executive positions in the US, Europe and the Middle East. He currently serves on the board of directors of US publicly-traded companies Supernus Pharmaceuticals, Inc., Raptor Pharmaceutical Corp., and Dimension Therapeutics a privately owned company. He is the Chairman of the boards of OxThera AB, and Orphazyme ApS.

From 2008 to 2009, Dr Gemayel was President and Chief Executive Officer of Altus Pharmaceuticals Inc., a publicly-traded pharmaceutical company. From 2003 to 2008, he was Executive Vice President at Genzyme Corporation where he was responsible for the company's global therapeutics, transplant, renal and biosurgery businesses. From 1988 to 2003, he held progressively senior roles at Hoffmann La-Roche and Roche Labs, most recently as Vice President, National Specialty Care, responsible for its US business for dermatology, oncology, transplantation, hepatitis and HIV.

Bernard Gilly said: "We are very pleased to welcome Georges to the Enterome Board. He has a wealth of experience in the global pharma industry and particularly in the clinical and commercial development of innovative products and disease management solutions. We look forward to the valuable contributions that he will make to the further the growth and development of Enterome."

Georges Gemayel added: "I am delighted to join Enterome at this exciting stage in its development, as it becomes poised to leverage its leadership in the understanding of the gut microbiome across drug discovery and diagnostics."

About Enterome:

Enterome is pioneering the development of novel drugs and diagnostics to support personalized therapies in microbiome-related diseases such as Inflammatory Bowel Diseases (IBD), metabolic diseases, and related disorders.

Enterome is also leading the development of new industry standards in gut microbiome quantitative and functional analysis. This technology leadership is allowing Enterome to open up the new field of therapeutic target discovery in the microbiome, and the study of the modulation of such targets by repositioning existing compounds to target this new organ to meet significant unmet medical needs.

The Company was established in 2012 in Paris, France, and has raised a total of €17.5m from leading venture capital investors (Seventure Partners, Lundbeckfond Ventures & Omnes Capital) and two strategic investors (Danone & Shire).

http://www.enterome.com

Contact

Pierre Belichard, CEO
+33-1-75-77-27-87

David Dible / Mark Swallow, Citigate Dewe Rogerson
+44-207-282-2949 / +44-207-282-2948
[email protected]
 

Suggested Articles

A TGen-led research team found that increased activity of the gene AEBP1 drives severe liver fibrosis in nonalcoholic steatohepatitis.

Days after announcing its R&D chief was stepping down, Gilead announced it will be buying a few of Novartis’ unwanted early-stage infection assets.

Mallinckrodt is teaming up with Silence Therapeutics to develop an RNAi program aimed at a group of proteins that play a part in promoting inflammation.